<?xml version='1.0' encoding='utf-8'?>
<document id="21098752"><sentence text="Phenobarbital/Lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy."><entity charOffset="0-13" id="DDI-PubMed.21098752.s1.e0" text="Phenobarbital" /><entity charOffset="14-25" id="DDI-PubMed.21098752.s1.e1" text="Lamotrigine" /><pair ddi="false" e1="DDI-PubMed.21098752.s1.e0" e2="DDI-PubMed.21098752.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s1.e0" e2="DDI-PubMed.21098752.s1.e1" /></sentence><sentence text="To report on a patient with epilepsy who developed leukopenia and thrombocytopenia during phenobarbital/lamotrigine treatment"><entity charOffset="104-115" id="DDI-PubMed.21098752.s2.e0" text="lamotrigine" /></sentence><sentence text="" /><sentence text="A 45-year-old woman with a 10-year history of complex partial seizures being treated with phenobarbital 100 mg/day presented due to the development of complex partial seizure episodes (8 episodes/month in the last 6 months)" /><sentence text=" Results of laboratory tests on admission showed normal platelets (250 x 10³/μL) and white blood cells (8" /><sentence text="2 x 10³/μL)" /><sentence text=" After clinical evaluation, lamotrigine titrated to a final dose of 100 mg twice daily was added to the phenobarbital"><entity charOffset="28-39" id="DDI-PubMed.21098752.s7.e0" text="lamotrigine" /><entity charOffset="104-117" id="DDI-PubMed.21098752.s7.e1" text="phenobarbital" /><pair ddi="false" e1="DDI-PubMed.21098752.s7.e0" e2="DDI-PubMed.21098752.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s7.e0" e2="DDI-PubMed.21098752.s7.e1" /></sentence><sentence text=" About 2 months later no epileptic manifestations were reported, but hematologic tests revealed a decrease in both platelets (36 x 10³/μL) and white blood cells (2" /><sentence text="0 x 10³/μL)" /><sentence text=" One day later, phenobarbital was discontinued and the patient developed 2 episodes of complex partial seizure"><entity charOffset="16-29" id="DDI-PubMed.21098752.s10.e0" text="phenobarbital" /></sentence><sentence text=" Levetiracetam titrated to 1500 mg/day was added to lamotrigine, with a normalization of platelets (260 x 10³/μL) and white blood cell (7"><entity charOffset="1-14" id="DDI-PubMed.21098752.s11.e0" text="Levetiracetam" /><entity charOffset="52-63" id="DDI-PubMed.21098752.s11.e1" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.21098752.s11.e0" e2="DDI-PubMed.21098752.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s11.e0" e2="DDI-PubMed.21098752.s11.e1" /></sentence><sentence text="9 x 10³/μL) counts about 20 days later" /><sentence text=" After a few days, levetiracetam was discontinued and phenobarbital rechallenge during lamotrigine treatment induced a new blood dyscrasia in about 2 weeks (platelets 80 x 10³/μL; white blood cells 3"><entity charOffset="19-32" id="DDI-PubMed.21098752.s13.e0" text="levetiracetam" /><entity charOffset="87-98" id="DDI-PubMed.21098752.s13.e1" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.21098752.s13.e0" e2="DDI-PubMed.21098752.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s13.e0" e2="DDI-PubMed.21098752.s13.e1" /></sentence><sentence text="2 x 10³/μL)" /><sentence text=" Phenobarbital was discontinued and levetiracetam was restarted, with a recovery of normal hematopoiesis in 25 days"><entity charOffset="36-49" id="DDI-PubMed.21098752.s15.e0" text="levetiracetam" /></sentence><sentence text=" The patient is presently receiving treatment with both lamotrigine 200 mg/day and levetiracetam 1500 mg/day and shows no seizure symptoms, blood abnormalities, or other adverse effects"><entity charOffset="56-67" id="DDI-PubMed.21098752.s16.e0" text="lamotrigine" /><entity charOffset="83-96" id="DDI-PubMed.21098752.s16.e1" text="levetiracetam" /><pair ddi="false" e1="DDI-PubMed.21098752.s16.e0" e2="DDI-PubMed.21098752.s16.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s16.e0" e2="DDI-PubMed.21098752.s16.e1" /></sentence><sentence text="" /><sentence text="Using the Horn Drug Interaction Probability Scale, we estimated a probable relationship between the drug-drug interaction and blood dyscrasia" /><sentence text=" The underlying mechanism of this interaction has not been well characterized" /><sentence text=" Cytochrome P450 enzyme induction by phenobarbital could be responsible for the production of reactive metabolites of lamotrigine that might be causative for the observed hematologic effects"><entity charOffset="118-129" id="DDI-PubMed.21098752.s20.e0" text="lamotrigine" /></sentence><sentence text=" A pharmacodynamic interaction between the 2 drugs is also a possible mechanism of this interaction" /><sentence text="" /><sentence text="Our patient with epilepsy developed blood dyscrasia during lamotrigine/phenobarbital treatment"><entity charOffset="59-70" id="DDI-PubMed.21098752.s23.e0" text="lamotrigine" /><entity charOffset="71-84" id="DDI-PubMed.21098752.s23.e1" text="phenobarbital" /><pair ddi="false" e1="DDI-PubMed.21098752.s23.e0" e2="DDI-PubMed.21098752.s23.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s23.e0" e2="DDI-PubMed.21098752.s23.e1" /></sentence><sentence text=" Clinicians should carefully monitor hematologic parameters during lamotrigine/phenobarbital treatment"><entity charOffset="67-78" id="DDI-PubMed.21098752.s24.e0" text="lamotrigine" /><entity charOffset="79-92" id="DDI-PubMed.21098752.s24.e1" text="phenobarbital" /><pair ddi="false" e1="DDI-PubMed.21098752.s24.e0" e2="DDI-PubMed.21098752.s24.e0" /><pair ddi="false" e1="DDI-PubMed.21098752.s24.e0" e2="DDI-PubMed.21098752.s24.e1" /></sentence><sentence text="" /></document>